Anavex Life Sciences (NASDAQ:AVXL) Announces Quarterly Earnings Results

Anavex Life Sciences (NASDAQ:AVXL) released its earnings results on Monday. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Trading Down 2.8 %

NASDAQ:AVXL opened at $10.87 on Wednesday. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $12.48. The stock has a market cap of $921.73 million, a price-to-earnings ratio of -21.74 and a beta of 0.73. The stock has a 50-day moving average price of $7.91 and a two-hundred day moving average price of $6.29.

Analysts Set New Price Targets

Several analysts recently commented on AVXL shares. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Anavex Life Sciences in a research note on Wednesday, November 27th. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Monday.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.